Current perspectives on premature ovarian failure



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Premature ovarian failure is a complex and multifactorial condition, the main clinical sign of which is persistent or intermittent amenorrhea lasting for at least four months. This condition is diagnosed at an age of up to 40 years. The relevance of this article lies in a more detailed examination of the causes, pathogenesis, and key clinical symptoms of premature ovarian failure. Particular attention is given to early diagnosis in women of young and middle reproductive age in order to optimize management strategies in the context of reproductive goals, as well as to the current state of scientific research. The review highlights several emerging therapeutic approaches that have shown promising results, including platelet-rich plasma (PRP) therapy, exosome-based therapy, in vitro follicle activation, stem cell therapy, microRNA-based strategies, and mitochondrial-targeted therapy. These experimental treatment strategies aim to stimulate oogenesis and folliculogenesis by enhancing natural biochemical pathways (neo-oofolliculogenesis) and improving the ovarian microenvironment.

 

Full Text

Restricted Access

About the authors

A. I. Tarasova

I.M. Sechenov First Moscow State Medical University

Author for correspondence.
Email: tarasova.a.2801@mail.ru
ORCID iD: 0009-0007-7764-7696
Russian Federation, Moscow

M. S. Pervushova

I.M. Sechenov First Moscow State Medical University

Email: masha.pervushova@mail.ru
ORCID iD: 0009-0005-9325-3713
Russian Federation, Moscow

Ya. V. Kirilenko

I.M. Sechenov First Moscow State Medical University

Email: yanchik15320155@gmail.com
ORCID iD: 0009-0004-1512-0707
Russian Federation, Moscow

M. V. Denisenko

MD GROUP Clinical Hospital «Mother and Child»

Email: margarita_pmc@mail.ru
ORCID iD: 0009-0007-7731-5114

MD, Cand. Sci. (Medicine)

Russian Federation, Moscow

E. A. Sosnova

I.M. Sechenov First Moscow State Medical University

Email: sosnova-elena@inbox.ru
ORCID iD: 0000-0002-1732-6870

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Moscow

References

  1. Tabeyeva GI, Shamilova NN, Zhakhur NF, et al. Premature ovarian failure is an enigma of the 21st century. Akusherstvo i Ginekologiya. 2013;(12):16–21. EDN: RTECLB
  2. Adamyan LV, Menzhinskaya IV, Antonova AA, Tonoyan N.M. Profile of serum autoantibodies in women with premature ovarian insufficiency receiving complex treatment using new surgical technologies. Russian Journal of Human Reproduction. 2024;30(2):32–41. doi: 10.17116/repro20243002132 EDN: BIULUH
  3. Dudareva YuA, Guryeva VA. Antenatal aspects of the formation of reproductive health. Russian Bulletin of Obstetrician-Gynecologist. 2017;17(6):19–24. doi: 10.17116/rosakush201717619-24 EDN: XHJQQP
  4. Strizhakov AN, Pashkov VM, Davydov AI. Nonoperative gynecology: training manual. Moscow: Sechenov University Publishing house; 2023. 335 р. (In Russ.)
  5. Jankowska K. Premature ovarian failure. Prz Menopauzalny. 2017;16(2):51–56. doi: 10.5114/pm.2017.68592
  6. Prasad S, Tiwari M, Pandey AN, et al. Impact of stress on oocyte quality and reproductive outcome. J Biomed Sci. 2016;23:36. doi: 10.1186/s12929-016-0253-4
  7. Chebotnikova TV. Premature ovarian insufficiency: expert opinion. Bulletin of Reproductive Health. 2007;(1):22–32. (In Russ.) EDN: RBAYHZ
  8. Gasparov AS, Dubinskaya ED, Titov DS, Lapteva NV. Clinical value of the ovarian reserve in reproductive function. Akusherstvo i Ginekologiya. 2014;(4):11–16. EDN: SHANRJ
  9. Mauri D, Gazouli I, Zarkavelis G, et al. Chemotherapy associated ovarian failure. Front Endocrinol. 2020;11:572388. doi: 10.3389/fendo.2020.572388
  10. Tkachenko LV, Gritsenko IA, Tikhaeva KYu, et al. Assessment of risk factors and prediction of premature ovarian failure. Obstetrics, Gynecology and Reproduction. 2022;16(1):73–80. doi: 10.17749/2313-7347/ob.gyn.rep.2021.273
  11. Jiang C, Gao T, Wang Y, et al. Birth weight and premature ovarian insufficiency: a systematic review and meta-analysis. Ovarian Res. 2024;17(1):74. doi: 10.1186/s13048-024-01357-9
  12. Clinical recommendations: Galactose metabolism disorders (Galactosemia). 2021–2022–2023 (31.08.2021). Approved by the Ministry of Health of the Russian Federation. Moscow; 2024. (In Russ.)
  13. Samoilovich YaA. Ovarian follicle aromatase p450 deficiency in normogonadotropic anovulation [dissertation]. Saint-Petersburg; 2016. 134 р. (In Russ.) EDN: VBHFOU
  14. Tsolin VA. Dynamic sofindicesofimmun. International Journal of Advanced Studies in Medicine and Biomedical Sciences. 2019;(1):102–105. EDN: ZSEBML
  15. Shamilova NN, Marchenko LA, Dolgushina NV, et al. Role of genetic and autoimmune disorders in the development of premature ovarian failure. Akusherstvo i Ginekologiya. 2012;(4-2):67–72. EDN: PIDMUV
  16. Panay N, Anderson RA, Nappi RE, et al. Premature ovarian insufficiency: an international menopause society white paper. Climacteric. 2020;23(5):426–446. doi: 10.1080/13697137.2020.1804547
  17. Ates S, Aydın S, Ozcan P, et al. Sleep, depression, anxiety and fatigue in women with premature ovarian insufficiency. J Psychosom Obstet Gynaecol. 2022;43(4):482–487. doi: 10.1080/0167482X.2022.2069008
  18. Blinov DV, Hasan PL, Mnatsakanyan AN, et al. Early menopause and premature ovarian insufficiency: problems and perspectives. Obstetrics, Gynecology and Reproduction. 2020;14(3):328–345. doi: 10.17749/2313-7347/ob.gyn.rep.2020.173 EDN: YOYBIN
  19. Averkova VG, Donnikov AE. Premature ovarian insufficiency: long-term health consequences and hormone replacement therapy strategies. Doctor.Ru. 2023;22(5):49–53. doi: 10.31550/1727-2378-2023-22-5-49-53 EDN: WCILCY
  20. van Kasteren YM, Schoemaker J. Premature ovarian failure: a systematic review on therapeutic interventions to restore ovarian function and achieve pregnancy. Hum Reprod Update. 1999;5(5):483–492. doi: 10.1093/humupd/5.5.483
  21. Webber L, Davies M, Anderson R, et al. ESHRE guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016;31(5):926–937. doi: 10.1093/humrep/dew027
  22. Sullivan SD, Sarrel PM, Nelson LM. Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause. Fertil Steril. 2016;106(7):1588–1599. doi: 10.1016/j.fertnstert.2016.09.046
  23. Koroleva V. Guide to managing patients with premature ovarian failure. How to assess, treat and allay patients’ fears: a quick guide. Practicing Gynecologist. 2025;(1):6. (In Russ.)
  24. Adamyan LV, Sibirskaya EV, Shcherina AV. Pathogenetic aspects of premature ovarian failure. Russian Journal of Human Reproduction. 2021;27(1):6–12. doi: 10.17116/repro2021270116 EDN: DACUOQ
  25. Naimi ZMS, Kalinina EA, Donnikov AE, et al. Role of vitamin D in the outcomes of assisted reproductive technology programs. Akusherstvo i Ginekologiya. 2015;(11):5–10. EDN: VAXPMN
  26. Patent RUS № 2750159 / 22.06.2021. Byul. № 18. Mashaeva RI, Marchenko LA, Olimpieva SP, et al. Method for diagnosis of premature ovarian insufficiency. Available from: https://www.elibrary.ru/download/elibrary_46316397_60967996.PDF (In Russ.) EDN: AHDTWN
  27. Yupatov EYu, Kurmanbaev TE, Shmidt AA, et al. Cryopreservation of reproductive tissue — the possibility of preserving fertility (a review). Russian Journal of Human Reproduction. 2020;26(5):99–106. doi: 10.17116/repro20202605199 EDN: UCZHBN
  28. Abdulaeva AS, Kuzmina PI, Bakhtiyarov KR. Possibilities of reproductive function realization in patients with premature ovarian insufficiency. Medical Council. 2024;18(4):30–36. doi: 10.21518/ms2024-126 EDN: IAESPI
  29. Xu YP, Fu JC, Hong ZL, et al. Psychological stressors involved in the pathogenesis of premature ovarian insufficiency and potential intervention measures. Gynecol Endocrinol. 2024;40(1):2360085. doi: 10.1080/09513590.2024.2360085
  30. Radzinsky VE, Ordiyants IM, Pobedinskaya OS. Modern technologies in treatment of patients with premature ovarian failure. Obstetrics and Gynecology. News. Views. Education. 2015;(3):123–136. EDN: VNTCIB
  31. Shikh EV. Comparative clinical pharmacological aspects of oral and transdermal dosage forms of estrogens. Obstetrics and Gynecology. News. Views. Education. 2016;(1):41–46. EDN: VQZJGH
  32. Adamyan LV, Alyasova AV, Mailova KS, Stepanyan A.A. Non-hormonal methods of treating premature ovarian insufficiency (POI). Russian Journal of Human Reproduction. 2024;30(2):6–14. doi: 10.17116/repro2024300216 EDN: GTVEXP
  33. Sfakianoudis K, Simopoulou M, Grigoriadis S, et al. Reactivating ovarian function through autologous platelet-rich plasma intraovarian infusion: pilot data on premature ovarian insufficiency, perimenopausal, menopausal, and poor responder women. J Clin Med. 2020;9(6):1809. doi: 10.3390/jcm9061809
  34. Hosseini L, Shirazi A, Naderi MM, et al. Platelet-rich plasma promotes the development of isolated human primordial and primary follicles to the preantral stage. Reprod Biomed Online. 2017;35(4):343–350. doi: 10.1016/j.rbmo.2017.04.007
  35. He F, Liu Y, Li T, et al. MicroRNA-146 attenuates lipopolysaccharide induced ovarian dysfunction by inhibiting the TLR4/NF-κB signaling pathway. Bioengineered. 2022;13(5):11611–11623. doi: 10.1080/21655979.2022.2070584
  36. Vitti Labs, LLC. A proof of concept study to evaluate exosomes from human mesenchymal stem cells in women with premature ovarian insufficiency (POI) (VL-POI-01). US Clinical Trials Registry. Clinical Trial NCT06072794. 2024 Sep.
  37. Huang QY, Chen SR, Chen JM, et al. Therapeutic options for premature ovarian insufficiency: an updated review. Reprod Biol Endocrinol. 2022;20(1):28. doi: 10.1186/s12958-022-00892-8
  38. Apolikhina IA, Saidova AS, Baranov II. Use of placental therapy in the correction of functional impairments in women: investigations and clinical practice. Akusherstvo i Ginekologiya. 2020;(3):203–210. doi: 10.18565/aig.2020.3.203-210 EDN: QFPOJB
  39. Savelyeva GM, Sukhykh GT, Manukhin IB, et al. Gynecology: national guidelines. Moscow: GEOTAR-Media Publ.; 2015, 704 p. (In Russ.) ISBN: 978-5-9704-3217-4
  40. Patent RUS № 2748246 / 21.05.2021. Byul. № 15. Adamyan LV, Smolnikova VYu, Asaturova AV, et al. One-step surgical method of ovarian function activation for treatment of premature ovarian insufficiency and restoration of ovarial function. Available from: https://www.elibrary.ru/download/elibrary_45812844_32988564.PDF (In Russ.) EDN: DZMHLN

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) Eco-Vector



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ:
ПИ № ФС 77 - 86335 от 11.12.2023 г.  
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ:
ЭЛ № ФС 77 - 80633 от 15.03.2021 г.